Cover Image
市場調查報告書

Anergis SA 產品平台分析

Anergis SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 289819
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Anergis SA 產品平台分析 Anergis SA - Product Pipeline Review - 2015
出版日期: 2015年04月22日 內容資訊: 英文 25 Pages
簡介

Anergis SA是總公司設置在瑞士的生物製藥企業,正在進行藥物研發、開發及銷售過敏的免疫療法治療藥。該公司利用由長鏈胜肽技術平台合成醫藥品級的重疊肽的專利來開發過敏的免疫療法治療藥。

本報告提供Anergis SA 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Anergis SA 基本資料

  • Anergis SA 概要
  • 主要資訊
  • 企業資料

Anergis SA :R&D概要

  • 主要的治療範圍

Anergis SA :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Anergis SA :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Anergis SA :藥物簡介

  • AllerT
  • AllerDM
  • AllerR
  • AllerG
  • AllerJ

Anergis SA :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Anergis SA :最新的開發平台資訊

Anergis SA :開發暫停中的計劃

Anergis SA :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06971CDB

Summary

Global Markets Direct's, 'Anergis SA - Product Pipeline Review - 2015', provides an overview of the Anergis SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Anergis SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Anergis SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Anergis SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Anergis SA's pipeline products

Reasons to buy

  • Evaluate Anergis SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Anergis SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Anergis SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Anergis SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Anergis SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Anergis SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Anergis SA Snapshot
    • Anergis SA Overview
    • Key Information
    • Key Facts
  • Anergis SA - Research and Development Overview
    • Key Therapeutic Areas
  • Anergis SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Anergis SA - Pipeline Products Glance
    • Anergis SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Anergis SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Anergis SA - Drug Profiles
    • AllerT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AllerDM
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AllerR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AllerG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AllerJ
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anergis SA - Pipeline Analysis
    • Anergis SA - Pipeline Products by Route of Administration
    • Anergis SA - Pipeline Products by Molecule Type
  • Anergis SA - Recent Pipeline Updates
  • Anergis SA - Dormant Projects
  • Anergis SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Anergis SA, Key Information
  • Anergis SA, Key Facts
  • Anergis SA - Pipeline by Indication, 2015
  • Anergis SA - Pipeline by Stage of Development, 2015
  • Anergis SA - Monotherapy Products in Pipeline, 2015
  • Anergis SA - Phase II, 2015
  • Anergis SA - Preclinical, 2015
  • Anergis SA - Discovery, 2015
  • Anergis SA - Pipeline by Route of Administration, 2015
  • Anergis SA - Pipeline by Molecule Type, 2015
  • Anergis SA - Recent Pipeline Updates, 2015
  • Anergis SA - Dormant Developmental Projects,2015

List of Figures

  • Anergis SA - Pipeline by Top 10 Indication, 2015
  • Anergis SA - Pipeline by Stage of Development, 2015
  • Anergis SA - Monotherapy Products in Pipeline, 2015
  • Anergis SA - Pipeline by Top 10 Route of Administration, 2015
  • Anergis SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top